-
Uncategorized3 weeks ago
Rhythm Bounces Back from Phase 3 Fail with FDA Nod for Rare Obesity Injection
At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.
-
Uncategorized3 weeks ago
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
-
Endpoints News3 weeks ago
Novo Holdings CEO discusses investments, geopolitics and China
The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein in...
-
Uncategorized3 weeks agoEvotec to receive $10m as kidney cancer trial launches
Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway. Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3...
-
Uncategorized3 weeks ago
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk...
-
Endpoints News3 weeks ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target,...
-
BioPharma Dive – AI / Data3 weeks agoRhythm obesity drug wins broader use from FDA
Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.
-
STAT News – Biotech3 weeks agoSTAT+: U.K. to take another look at cost-effectiveness of Alzheimer’s drugs
LONDON — U.K. health officials on Friday said they had reopened a review of two new Alzheimer’s therapies after previously finding they did not provide good...
-
Uncategorized3 weeks agoLilly wins appeal for donanemab, drug to be reconsidered for NHS
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for...
-
Endpoints News3 weeks ago
Idorsia looks for another CEO — again; Former Jazz exec makes a comeback
→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search. Idorsia’s...
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
